Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...

Libtayo could capture up to $1 billion in sales from the NSCLC category, according to analysts, although additional upside is possible if an ongoing combination study yields positive results.

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

Libtayo reached $367M in Q4 global sales ... Sanofi development balance is fully repaid in 2026. Analysts: Slightly positive, ...

Anticipated pivotal data readouts include itepekimab for COPD in mid-2025 and a combination study of fianlimab and Libtayo for melanoma in the second half of 2025. Revenues from the Sanofi ...

Anticipation surrounds Regeneron Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive ... lowering; Libtayo in oncology; and Kevzara ...

Regeneron Pharmaceuticals has received a total of 10 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $797.9, the consensus suggests a potential 32.4% ...